Xeris Biopharma Holdings, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for XERS, updated each market day.
XERS AI Sentiment
AI sees no strong directional signal for Xeris Biopharma Holdings, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Xeris Biopharma Holdings, Inc. Common Stock
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Sector
Exchange
Market Cap
$1,036,312,052
Cap Tier
Employees
435
Headquarters
CHICAGO, IL
Listed Since
June 21, 2018
Website
XERS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
XERS Volatility
Xeris Biopharma Holdings, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
